TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Xilio Therapeutics ( (XLO) ).
On November 21, 2025, Xilio Therapeutics held a special meeting where stockholders approved the 2025 Stock Incentive Plan and a one-time repricing of certain employee stock options. The repricing adjusted the exercise price of stock options for key executives, impacting the company’s operational and financial strategies by potentially enhancing employee retention and motivation.
The most recent analyst rating on (XLO) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
Spark’s Take on XLO Stock
According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.
Xilio Therapeutics receives a moderate score due to a mix of promising strategic partnerships and ongoing financial challenges. The partnership with AbbVie is a notable positive, providing potential financial and strategic benefits. However, the company’s current lack of profitability and negative cash flow impact the overall evaluation. Technical analysis indicates short-term momentum, but longer-term trends remain a concern. The valuation reflects the company’s current unprofitability.
To see Spark’s full report on XLO stock, click here.
More about Xilio Therapeutics
Xilio Therapeutics, Inc. operates within the biotechnology industry, focusing on developing innovative therapies for cancer treatment. The company’s primary products and services include the development of tumor-selective immuno-oncology therapies, with a market focus on addressing unmet needs in cancer care.
Average Trading Volume: 761,452
Technical Sentiment Signal: Sell
Current Market Cap: $39.5M
See more data about XLO stock on TipRanks’ Stock Analysis page.